Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

Oceania forecasts sales lift as it targets debt
Property

Oceania forecasts sales lift as it targets debt

It said sales applications had lifted 23% between July and August.

New structure, powers for ComCom
Markets

New structure, powers for ComCom

Groceries, aviation, building supplies, digital services carparking all get a mention.

NZME shareholder Jim Grenon lifts investment in media firm
Markets

NZME shareholder Jim Grenon lifts investment in media firm

NZME shareholder and director Jim Grenon has lifted his investment in the media business for the second time in recent weeks, to just under 18%.A notice to the NZX on Monday stated Grenon had lifted his shareholding from 15.963% to 17.932%, after acquiring 3.7 million shares for...

F&P Healthcare urges Govt to shut patent loophole
Markets

F&P Healthcare urges Govt to shut patent loophole

The company says the current patent loophole threatens its NZ operations.